Prolactin-releasing peptide: a new tool for obesity treatment

. 2016 Aug ; 230 (2) : R51-8.

Jazyk angličtina Země Anglie, Velká Británie Médium print

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid27418033

Obesity is an escalating epidemic, but an effective noninvasive therapy is still scarce. For obesity treatment, anorexigenic neuropeptides are promising tools, but their delivery from the periphery to the brain is complicated because peptides have a low stability and limited ability to cross the blood-brain barrier. In this review, we summarize results of several studies with our newly designed lipidized analogs of prolactin-releasing peptide (PrRP). PrRP is involved in feeding and energy balance regulation as demonstrated by obesity phenotypes of both PrRP- and PrRP-receptor-knockout mice. Lipidized PrRP analogs showed binding affinity and signaling in PrRP receptor-expressing cells similar to natural PrRP. Moreover, these analogs showed high binding affinity also to anorexigenic neuropeptide FF (NPFF)-2 receptor. Acute peripheral administration of myristoylated and palmitoylated PrRP analogs to mice and rats induced strong and long-lasting anorexigenic effects and neuronal activation in the brain areas involved in food intake regulation. Two-week-long subcutaneous administration of palmitoylated PrRP31 and myristoylated PrRP20 lowered food intake, body weight, improved metabolic parameters and attenuated lipogenesis in mice with diet-induced obesity. A strong anorexigenic, body weight-reducing and glucose tolerance-improving effect of palmitoylated-PrRP31 was shown also in diet-induced obese rats after its repeated 2-week-long peripheral administration. Thus, the strong anorexigenic and body weight-reducing effects of palmitoylated PrRP31 and myristoylated PrRP20 make these analogs attractive candidates for antiobesity treatment. Moreover, PrRP receptor might be a new target for obesity therapy.

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

Lipidization as a tool toward peptide therapeutics

. 2023 Dec ; 30 (1) : 2284685. [epub] 20231127

NPFFR2-deficient mice fed a high-fat diet develop strong intolerance to glucose

. 2023 May 31 ; 137 (10) : 847-862.

Metabolomic Study of Aging in fa/fa Rats: Multiplatform Urine and Serum Analysis

. 2023 Apr 12 ; 13 (4) : . [epub] 20230412

Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances

. 2022 May 19 ; 12 (1) : 26. [epub] 20220519

Lipidized Prolactin-Releasing Peptide as a New Potential Tool to Treat Obesity and Type 2 Diabetes Mellitus: Preclinical Studies in Rodent Models

. 2021 ; 12 () : 779962. [epub] 20211118

Cholecystokinin system is involved in the anorexigenic effect of peripherally applied palmitoylated prolactin-releasing peptide in fasted mice

. 2021 Aug 31 ; 70 (4) : 579-590. [epub] 20210601

Cellular Signaling and Anti-Apoptotic Effects of Prolactin-Releasing Peptide and Its Analog on SH-SY5Y Cells

. 2020 Sep 01 ; 21 (17) : . [epub] 20200901

Prolactin-Releasing Peptide: Physiological and Pharmacological Properties

. 2019 Oct 24 ; 20 (21) : . [epub] 20191024

Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study

. 2018 Jan 16 ; 8 (1) : 5. [epub] 20180116

Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity

. 2017 ; 12 (8) : e0183449. [epub] 20170818

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...